Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Krystal Biotech (KRYS)

Krystal Biotech Q2 2025 revenue rises to $96.0 million; net income $38.3 million

Positive Impact 3 of 5 earnings Written later

Krystal Biotech reported second-quarter 2025 product revenue of $96.0 million, up from $70.3 million a year earlier, and net income of $38.3 million, or $1.29 per diluted share, compared with $15.6 million, or $0.53 per diluted share, in the prior-year quarter. The company also reported $820.8 million in cash and investments and issued FY 2025 non-GAAP R&D and SG&A expense guidance of $150.0 million to $175.0 million.

Key points

  • Q2 2025 product revenue, net: $96.0 million vs. $70.3 million in Q2 2024
  • Q2 2025 net income: $38.3 million ($1.29 per diluted share) vs. $15.6 million ($0.53) a year earlier
  • Cash, cash equivalents and investments: $820.8 million as of June 30, 2025
  • FY 2025 non-GAAP R&D and SG&A expense guidance: $150.0 million to $175.0 million

The filing

CompanyKrystal Biotech (KRYS)
Form8-K, current report
Filed with the SECAug 4, 2025, 7:09 AM ET
Accession number0001711279-25-000078

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.